Literature DB >> 8565446

The reliability of distinguishing primary versus secondary negative symptoms.

M Flaum1, N Andreasen.   

Abstract

The objective appearance of negative symptoms in schizophrenia and other psychotic disorders may be a direct reflection of a primary neural abnormality or may be secondary to a variety of factors such as neuroleptic side effects, depression, positive symptoms, or environmental understimulation. Although there is a consensus that it is important to be able to disentangle "primary" versus "secondary" negative symptoms, optimal strategies for doing so remain unclear. Concerns have been raised about making this distinction based on clinical judgment because of potential low reliability in the absence of extensive training and/or highly specialized rating scales. This is particularly important in terms of the application of DSM-IV criteria for schizophrenia, in which negative symptoms play a prominent role. In the context of the DSM-IV schizophrenia field trial project, we examined the reliability of making the primary versus secondary distinction in a multicenter sample of 462 subjects with nonorganic psychotic disorders. Each subject was assessed by two raters, half in an interrater design (i.e., conjoint interviews) and half in a test-retest design (i.e., independent interviews by two raters conducted 1 day apart). All raters used the same semistructured interview instrument, which included an abbreviated version of the Scale for the Assessment of Negative Symptoms (SANS). In addition to the usual SANS ratings, raters were asked to indicate their judgment as to whether the symptom was primary, secondary, or unknown (inadequate information to assess). No formal training was provided. Reliability, as quantified by kapp, indicated only a fair degree of agreement ranging from 0.48 to 0.68 for interrater reliability (median, 0.50) and 0.34 to 0.66 for test-retest reliability (median, 0.38). Negative symptoms were rated as primary approximately twice as often as secondary, and raters believed they had adequate information to make this distinction based only on cross-sectional evaluation in all but 10% of the cases. These data suggest that the primary versus secondary distinction should not be incorporated into the application of operationalized diagnostic criteria. Implications are discussed in terms of balancing reliability and validity in the assessment of negative symptoms.

Entities:  

Mesh:

Year:  1995        PMID: 8565446     DOI: 10.1016/s0010-440x(95)90249-x

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  10 in total

1.  Early-Stage Negative Symptom Trajectories and Relationships With 13-Year Outcomes in First-Episode Nonaffective Psychosis.

Authors:  Wing Chung Chang; Ryan Wui Hang Ho; Jennifer Yee Man Tang; Corine Sau Man Wong; Christy Lai Ming Hui; Sherry K W Chan; Edwin M H Lee; Yi Nam Suen; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

2.  [Negative symptoms of schizophrenic patients from the perspective of psychiatrists, patients themselves and their relatives].

Authors:  R Bottlender; M Jäger; I Kunze; C Groll; I Borski; H-J Möller
Journal:  Nervenarzt       Date:  2003-09       Impact factor: 1.214

Review 3.  Toward defining schizophrenia as a more useful clinical concept.

Authors:  Jess G Fiedorowicz; Eric A Epping; Michael Flaum
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

4.  Development of schizotypal symptoms following psychiatric disorders in childhood or adolescence.

Authors:  Selene S A A Fagel; Hanna Swaab; Leo M J De Sonneville; Sophie Van Rijn; Jolijn K Pieterse; Floor Scheepers; Herman Van Engeland
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-04-07       Impact factor: 4.785

5.  Factor Structure, Convergent, and Divergent Validity of the Prodromal Questionnaire-Negative Symptom Subscale.

Authors:  Katherine M Pierce; Seth D Maxwell; Thomas M Olino; Shanna Cooper; Lauren M Ellman
Journal:  Assessment       Date:  2020-01-19

Review 6.  Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

Authors:  Pierre Chue; Justine K Lalonde
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-08       Impact factor: 2.570

7.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

8.  Chronic Administration of 13-cis-retinoic Acid Induces Depression-Like Behavior by Altering the Activity of Dentate Granule Cells.

Authors:  Xiao-Hong Su; Wei-Peng Li; Yi-Jie Wang; Jia Liu; Jun-Yu Liu; Ying Jiang; Fu-Hua Peng
Journal:  Neurotherapeutics       Date:  2021-12-10       Impact factor: 6.088

9.  The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms.

Authors:  Christine Wyss; Konrad Hitz; Michael P Hengartner; Anastasia Theodoridou; Caitriona Obermann; Idun Uhl; Patrik Roser; Edna Grünblatt; Erich Seifritz; Georg Juckel; Wolfram Kawohl
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

10.  The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness.

Authors:  Teresa Vargas; Anthony O Ahmed; Gregory P Strauss; Cassandra M Brandes; Elaine F Walker; Robert W Buchanan; James M Gold; Vijay A Mittal
Journal:  Transl Psychiatry       Date:  2019-09-16       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.